Theranostics · Literature Radar
PRRT evidence for neuroendocrine tumours — NETTER-1 / NETTER-2 / NETTER-P / first-line questions. Curated daily from Europe PMC (PubMed + PMC + preprints) and OpenAlex — free-full-text link on each open-access paper.
Garabedian N, Zaragori T, Tabouret E, Taillandier L et al.
Evidence supporting the efficacy and safety of [¹⁷⁷Lu]Lu-DOTATATE in refractory meningiomas derives mainly from small, single-center studies. The French national multicenter MELUTE study aimed to cons…
Piekarski E, Cottereau AS, Coriat R, Willems L et al.
Neuroendocrine tumors (NETs) are often associated with paraneoplastic features including carcinoid syndrome in up to 30% to 40% of cases. However, paraneoplastic thrombocytosis is a rare NET-associate…
Becx MN, van Treijen MJC, Brabander T, de Herder WW et al.
IntroductionMultiple endocrine neoplasia type 1 (MEN1) is the most common genetic syndrome causing neuroendocrine tumours (NET) with metastatic duodenopancreatic NET (dpNET) forming the predominant ca…
Wada N, Kawata S, Obata Y, Tomimaru Y et al.
Pheochromocytomas and paragangliomas (PPGLs) are neuroendocrine tumors derived from chromaffin cells that produce catecholamines. The primary treatment for PPGLs is surgical resection, and even in cas…
Sridhar A, Behiri N, Klubo-Gwiezdzinska J.
The incidental thyroid uptake of radiolabeled ligands used in positron emission tomography/computed tomography (PET/CT) targeting cell-surface proteins is observed in up to 6% of all scans. While diff…
Ganguly T, Harris RE, Hausner SH, Sutcliffe JL.
Pancreatic ductal adenocarcinoma is one of the most lethal malignances worldwide, and there remains an urgent need for more effective and less toxic treatment strategies. Integrin αvβ₆ is a cell-surfa…
van Heerden J, Kruger M, Reddy K, van Zyl A et al.
BackgroundIn South Africa, the metastatic response rate for stage 4 high-risk neuroblastoma (HR-NB) to induction chemotherapy is lower than that of similar regimens in well-resourced settings. Augment…
Li S, Maes J, Maes A, Rottey S et al.
Somatostatin receptor (SSTR)-targeted imaging and therapy are established approaches for neuroendocrine tumors, but accumulating evidence indicates that SSTRs are also expressed in various non-neuroen…
Fidelman N, Chan K, Keenan BP, Oh DY et al.
PurposeObjective responses to peptide receptor radionuclide therapy (PRRT) for pre-treated patients with well-differentiated neuroendocrine tumors (WD-NET) and Ki-67 index >10% may not be durable. Res…
Bodei L, Ziv E, Mauguen A, Zanzonico P et al.
Patients with well-differentiated neuroendocrine tumors (NETs) frequently present with liver-dominant metastases, which significantly impact prognosis and limit curative options. Although standard int…
Bodei L, Zanzonico P, Krebs S, Reidy-Lagunes D et al.
Neuroendocrine tumors (NETs) are often detected late, limiting curative treatments and requiring systemic therapies such as peptide receptor radionuclide therapy (PRRT). Although ¹⁷⁷Lu-DOTATATE has de…
Fincher L, Cara C, Mckay E, Butler SP.
Peptide receptor radionuclide therapy (PRRT) with [¹⁷⁷Lu]Lu-DOTATATE is a well-established treatment for advanced gastroenteropancreatic neuroendocrine tumours. After transition from a carrier added (…
Pacella S, Elisei F, Mattoli MV, Airò Farulla LS et al.
BackgroundPheochromocytomas and paragangliomas (PPGL) are rare and heterogeneous neuroendocrine tumors for which therapeutic options remain limited, particularly in the metastatic or progressive setti…
Essler M, Veit N, Müller A, Marinova M et al.
Peptide receptor radionuclide therapy (PRRT) with ¹⁷⁷Lu-DOTATATE improves outcomes in neuroendocrine tumors (NETs), yet durable disease control remains limited in progressive pancreatic NET (pNET) and…
Nieri A, Imperiale A, Urso L.
Lee L, Ito T, Jensen RT.
IntroductionSomatostatin receptors (SSTRs) have played a central role in all aspects of the management of neuroendocrine/endocrine neoplasms (NENs). This includes in diagnosis of NENs with the widespr…
Spetz JKE, Montelius ME, Berger E, Johansson JAM et al.
BackgroundPeptide receptor radionuclide therapy with [177Lu]Lu-DOTATATE is an established treatment for somatostatin receptor-expressing neuroendocrine tumors. Although strong anti-tumor effects have …
Sen Wang, Shoujun Tang, ShengJie Tang, Chun Wang et al.
Radioligand therapy (RLT) delivers therapeutic radionuclides to tumor-associated targets through specific targeting ligands and has demonstrated substantial clinical value in malignancies such as pros…
Wahl RL, Dewaraja YK.
Radiopharmaceutical therapy (RPT) is growing in clinical importance and utilization. First-generation RPTs such as 131I-tositumomab (Bexxar) radioimmunotherapy of lymphoma used simplified whole-body d…
Silva BTD, Maia A, Pereira MT, Santos S et al.
Neuroendocrine tumors (NETs) are rare neoplasms that present significant challenges during pregnancy, particularly in the context of metastatic disease or carcinoid syndrome requiring systemic therapy…
Kvassheim M, Karlberg A, Blakkisrud J, Stokke C.
Biokinetics for potential alpha-emitter peptide receptor radionuclide therapies (PRRTs) were simulated to estimate tumour-to-kidney absorbed dose ratios for 225Ac, 227Th, 212Pb, 230U, 226Ac, 211At, an…
Ariadni Spyroglou, Pernille Holmager, Krystallenia I. Alexandraki
Neuroendocrine neoplasms (NENs) arising from neuroendocrine cells can develop throughout the body from pituitary to thyroid and paraganglion or the gastroenteropancreatic (GEP) and bronchopulmonary (B…
McCall M, Stevenson J, Chan B.
Head and neck paragangliomas present incidentally or with signs of mass effect. Approximately 30%-40% are hereditary, which typically present at a younger age. Given their proximity to vital structure…
Weirong Shi, Limin Zhang, Xinyue Feng, Jiayu Liu et al.
Lutetium-177 ( 177 Lu)–based Radioligand Therapy (RLT) has emerged as an important modality in precision oncology, with demonstrated clinical benefit in selected malignancies. Its clinical relevance i…
Dong Z, Jin X, Meng X, Liu W et al.
ObjectiveQuantitative imaging-based dosimetry is essential for optimizing [177Lu]Lu-DOTATATE peptide receptor radionuclide therapy (PRRT), yet full multi-time-point (MTP) SPECT/CT is difficult to impl…
Kurisaki M, Nakano E, Sakai Y, Kase M et al.
Merkel cell carcinoma (MCC) is a highly aggressive neuroendocrine skin cancer associated with early metastasis and poor outcomes in the advanced stages. Immune checkpoint inhibitors (ICIs), particular…
Musiałkiewicz J, Komarnicki P, Maciejewski A, Ziółkowska P et al.
Montanini F, Imperiale A, Monaci A, Valente S et al.
177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) is an established therapeutic option for patients with neuroendocrine tumors (NETs). Although radiomics has been increasingly applied in NET…
Guo W, Fan C, Chen Y, Yu S et al.
Rapid radiopharmaceutical clearance limits the efficacy of peptide receptor radionuclide therapy (PRRT) for the treatment of advanced neuroendocrine tumors (NETs). In this prospective, single-center, …
Koch R, Pegna G, Mallak N, Winters C et al.
ContextTheranostics has emerged as a precision medicine paradigm in neuroendocrine tumors (NETs), integrating receptor-based imaging with targeted radionuclide therapy to individualize treatment. This…
Salomonsson SL, Engbers PAM, Nonnekens J, Bondza S.
G protein-coupled receptors (GPCRs) are the target for approximately 36% of approved drugs and control many cell signaling pathways. Among these is the somatostatin receptor 2 (SSTR2), which can be ta…
Konishi K, Wakabayashi K, Ikenohira T, Yamashita R et al.
Background/aimQuantitative post-therapy single-photon emission computed tomography/computed tomography (SPECT/CT) may offer valuable insights for response assessment during peptide receptor radionucli…
Schwarz JL, Williams JK, Keutgen XM, Liao CY.
Radiolabeled somatostatin analogs are increasingly used in the diagnosis and treatment of neuroendocrine tumors. Diagnostic imaging with 68Ga-DOTATATE PET/CT has demonstrated the improved sensitivity …
Mallareddy Banala, Shabbir Ezuddin, Mark Foley, Russ Kuker
Artificial intelligence (AI) has been studied across radiopharmaceutical therapy (RPT); however, evidence for treatment-changing use remains limited. We conducted a structured narrative review with de…
D. Coll Segarra, S. Arias Soriano, S.V. Tipnis, J.A. Nye
INTRODUCTION: A practical approach is presented to reliably detect and quantify the long-lived contaminant 177m Lu commonly found in 177 Lu-based therapeutics. OBJECTIVE: The objective of this work wa…
Christian A. Dascalescu, Felix L. Herr, R. Ebner, Victoria Fusch et al.
BACKGROUND: Purpose of this study is to evaluate the value of a routinely available baseline SSTR-PET imaging parameter, the Krenning score (KS), within integrated biomarker models for overall surviva…
Alexandra Litvinenko, Hélène Koch, Gianluca Corsanici, Giulia Battistini et al.
Nuclear theranostics has transitioned from proof-of-concept to clinical practice with the regulatory approval of SSTR- and PSMA-targeted radioligand therapies. However, therapeutic outcomes remain con…
Rishi Chakraborty
Peptide Receptor Radionuclide Therapy (PRRT) Lu-177 DOTATATE resistance in well-differentiated Grade 3 Neuroendocrine Tumors (NETs) is a type of acquired therapeutic resistance in well differentiated …
Narendra Rathod
The application of artificial intelligence (AI) in positron emission tomography (PET)-based internal dosimetry in radiopharmaceutical therapy (RPT), with an emphasis on the paradigm shift from resourc…
S.V. Tipnis, William J. Rieter
Our results show the exposures throughout the course of treatment are well below the Nuclear Regulatory Commission release criteria of 500 mrem. Thus, patients pose little risk in terms of radiation s…
Al-Ramadhani AQM, Şenışık AM, Kovan B, Mutlu E et al.
Quantitative post-therapy 177Lu SPECT depends on reliable attenuation correction. For centers without SPECT/CT, CT-free Chang attenuation correction is feasible, but its dependence on emission-derived…
Ferraù F, Blanca ES, Costa CP, Cannavò S.
Peptide receptor radionuclide therapy (PRRT) is an emerging and promising targeted treatment for aggressive pituitary neuroendocrine tumours (PitNETs) and pituitary carcinomas refractory to convention…
Bakr H, Al-Awar A, Spetz JK, Forssell-Aronsson EB.
Gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) are the most common subtype of NETs, and their incidence continues to increase worldwide. Many NETs express somatostatin receptors (SSTRs), en…
Zhang S, Deng J, Zhang N, Bai X et al.
PurposeTo evaluate the feasibility, safety and preliminary efficacy of dual-targeted radioligand therapy combining [177Lu]Lu-DOTATATE and [177Lu]Lu-DOTA-IBA in patients with bone metastases from neuro…
Warfvinge CF, Kapidzic SC, Gustafsson J, Jessen L et al.
[177Lu]Lu-DOTATATE is an established treatment for metastasized neuroendocrine tumors (NETs). It is postulated that a higher tumor absorbed dose (AD) improves clinical efficacy. The aim of this study …
Schwengber WK, Sanders J, Pinteric A, Armitage L et al.
Radiopharmaceutical therapy (RPT) uses radionuclides linked to targeting ligands to bind tumor-associated receptors or antigens and deliver ionizing radiation to malignant cells. Approved agents inclu…
Veličković F, Vlajković M, Macut Đ, Stević M.
The aim of this retrospective study is to analyze the outcome and survival of patients with well-differentiated metastatic neuroendocrine neoplasm (NEN) treated with peptide receptor radionuclide ther…
Bagasariya R, Parghane RV, Shetty N, Gala K et al.
BackgroundGastroenteropancreatic neuroendocrine tumors (GEP-NETs) demonstrating liver-dominant inoperable metastatic diseases or locally advanced inoperable tumors may at times show reduced efficacy f…
Parghane RV, Basu S.
The landscape of systemic treatment for patients with neuroendocrine tumors (NET) is continuously evolving due to discovery of various molecular pathways involvement in tumor growth and the clinical a…
Andersson M, Opsomer T, Saldarriaga Vargas C.
The β--emitter 161Tb is emerging as a promising radionuclide for radiopharmaceutical therapy because of its increased yield of low-energy electrons compared with 177Lu. This results in an increased lo…
Chopra S, Xu T, Berglund H, Gustafsson A et al.
BackgroundNeuroblastoma is an aggressive paediatric malignancy with poor outcomes in high-risk patients despite multimodal therapy. [177Lu]Lu-DOTATATE, targeting somatostatin receptor 2 (SSTR2), is un…
Tsuchiya J, Narita T, Anzai T, Koyama S et al.
Objective¹⁷⁷Lu is an approved radionuclide for targeted radionuclide therapy (TRT), first established with ¹⁷⁷Lu-DOTATATE for neuroendocrine tumors, and subsequently with PSMA-targeted therapy. The wi…
Yan Y, Liu X, Jiang Y, Sun L.
Radionuclide drug conjugates (RDCs) are emerging molecular platforms for diagnostic imaging, targeted radionuclide therapy, and precision-oncology theranostics. Theranostic applications typically empl…
Bagasariya R, Sonavane S, Basu S.
False-positive findings on molecular imaging can pose significant diagnostic dilemmas in oncological cases. We report an elderly woman with metastatic neuroendocrine tumor of unknown primary who under…
Perrone E, Ghai K, Eismant A, Greifenstein L et al.
A 45-year-old woman with heavily pretreated, recurrent metastatic esthesioneuroblastoma and progressive symptomatic disease underwent first-in-human peptide receptor radionuclide therapy (PRRT) using …
Ytterbrink C, Pettersson D, Shubbar E, Helou K et al.
Patients with neuroendocrine tumours may receive higher total amount of [177Lu]Lu-DOTA-(Tyr3)-octreotate and achieve better tumor control if the risk of kidney toxicity could be predicted individually…
Hernandez-Felix JH, Golagha M, Jha A, Varghese D et al.
Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors of neural crest origin that exhibit wide clinical and biological heterogeneity. While surgical resection remains the only cu…
Hernandez-Felix JH, Lagana M, Cosentini D, Tacchetti MC et al.
Adrenal malignancies include adrenocortical carcinoma (ACC) and pheochromocytoma/paraganglioma (PPGL), rare endocrine tumors that share an adrenal or extra-adrenal location but differ substantially in…
Furuya Y, Tsujimoto M, Asai T, Iwama I et al.
ObjectiveAs the incidence of neuroendocrine tumors (NETs) increases, Lutetium-177 (Lu-177) DOTATATE targeted radionuclide therapy (TRT) has become a vital treatment strategy. However, its prolonged co…
Lancova L, Kracmerova T.
Somatostatin receptor therapy (SSRT) with [177Lu]Lu-oxodotreotide is an established treatment for metastatic neuroendocrine tumours. However, radiation protection guidelines for patients with stomas r…
Showing the 60 most recent of 120 papers in this topic.Browse every paper →
Request brochure
Tell us who you are and we’ll send the full product brochure to your institutional email after a quick review. We respond within one working day (Mon–Fri, 9:30–18:30 IST).
A Saxsons sales engineer will review your request and send the brochure to your institutional email within one working day. You may receive a verification call before processing.
